Enveric Biosciences, Inc. 8-K

What Happened
Enveric Biosciences, Inc. (ENVB) filed additional proxy materials on April 30, 2026 to correct typographical errors in its definitive proxy statement (originally filed April 14, 2026) for the 2026 Annual Meeting of Stockholders on May 28, 2026 at 10:00 a.m. ET. The correction clarifies the proposed reverse stock split range: the correct ratio is 1-for-5 to 1-for-15 (previously and incorrectly shown in two places as 1-for-5 to 1-for-50). The Board retains discretion to choose the final ratio within the 1-for-5 to 1-for-15 range and would announce the chosen ratio publicly if implemented.

Key Details

• Proxy correction filed on April 30, 2026 (Additional Proxy Materials; Exhibit 99.1 to the 8-K).
• Annual Meeting: May 28, 2026 at 10:00 a.m. ET; items include election of six directors, say-on-pay, reverse stock split approval, authorized shares increase, auditor ratification, and possible adjournment.
• Reverse Stock Split Proposal: corrected Range is 1-for-5 to 1-for-15 (was mistakenly printed as 1-for-5 to 1-for-50 in two sections).
• Authorized Stock Increase Proposal would raise authorized common shares from 100,000,000 to 5,000,000,000 if approved. No change to meeting location, record date, or other proposals.

Why It Matters
This filing fixes a material disclosure error about the maximum reverse split ratio, ensuring shareholders have accurate information before voting. A reverse stock split (if later approved and implemented) would consolidate outstanding shares at a ratio chosen by the Board within the corrected 1-for-5 to 1-for-15 range, which could change the per‑share price and share count but does not by itself alter the company’s market value. The authorized shares increase proposal, if approved, would expand the company’s ability to issue additional shares in the future and could have dilution implications. Retail investors should review the corrected proxy materials to understand these proposals and their potential effects before casting votes.